Clinical TrialJun 9, 2026, 04:12 PM
Nasus Pharma NS003 Preclinical Study Shows Positive PK & Safety Results
AI Summary
Nasus Pharma Ltd. announced positive results from a preclinical pharmacokinetic and safety study of NS003, its intranasal ondansetron formulation for chemotherapy and post-operative nausea and vomiting. The study showed NS003 had a comparable pharmacokinetic profile to intravenous ondansetron and a favorable safety profile. Following these results, the company plans to advance NS003 to a first-in-human PK study in the third quarter of 2026, further expanding its intranasal product portfolio.
Key Highlights
- Nasus Pharma announced positive preclinical pharmacokinetic and safety results for NS003.
- NS003, an intranasal ondansetron formulation, showed a comparable PK profile to intravenous ondansetron in animal studies.
- The study demonstrated a favorable safety profile for NS003 at four times the test dose.
- The company plans to initiate a first-in-human PK study for NS003 in the third quarter of 2026.
- Nasus Pharma also expects to begin the pivotal study for NS002 (anaphylaxis) in the fourth quarter of 2026.
- Ondansetron had over 12 million prescriptions for 6 million patients in 2023, with Zofran peak sales exceeding $1.5 billion.
- NS003 aims to address breakthrough nausea and vomiting in 15-20% of chemotherapy and radiotherapy patients.
Price Impact